Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond

A groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment.

This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and holds potential for broader applications, including solid tumors like prostate cancer. The research builds on the success of mRNA-LNP technology, widely known from COVID-19 vaccines, and could transform immunotherapy by making it less invasive and more scalable.The study focused on preclinical experiments in mice with B-cell lymphoma, a type of blood cancer.
Researchers injected LNPs containing mRNA encoding a CAR that targets CD19, a protein on lymphoma cells. The LNPs were engineered with a protein to specifically target T cells, ensuring precise delivery. The approach generated approximately 3 million CAR-T cells per mouse, comparable to the 2–10 million cells used in conventional human CAR-T therapy, which involves extracting, modifying, and reinfusing T cells. Using noninvasive bioluminescence imaging, the team tracked the CAR-T cells, confirming their proliferation, accurate tumor targeting, and ability to destroy lymphoma tumors. The results mirrored those of traditional CAR-T therapy, with treated mice showing significant tumor regression and prolonged survival. The LNPs primarily targeted T cells with minimal off-target effects, and no significant toxicity was observed, indicating the method’s safety.
While the experiments centered on B-cell lymphoma, the researchers highlighted the mRNA-LNP platform’s versatility, suggesting it could be adapted for other cancers, including solid tumors like prostate cancer, which have been challenging for CAR-T therapy due to immunosuppressive tumor microenvironments and the difficulty of identifying suitable antigens. By modifying the mRNA to encode CARs targeting antigens like PSMA (prostate-specific membrane antigen) for prostate cancer, the in situ method could be tailored to attack solid tumors. The approach’s ability to generate CAR-T cells directly in the body could enable repeated dosing or sequential targeting of multiple antigens, potentially overcoming the heterogeneity of solid tumors. Although the study did not test solid tumors, its success in lymphoma provides a foundation for future research into cancers like prostate, lung, breast, and pancreatic cancer. The method’s simplicity could also reduce costs and logistical barriers, making CAR-T therapy more accessible for patients with advanced prostate cancer, where treatments like surgery or hormone therapy often fall short.

The researchers plan to refine the method and test it in larger animal models, a critical step toward human trials. For solid tumors, future experiments will need to validate antigen targets, overcome tumor microenvironment barriers, and optimize LNP delivery to tumor sites, potentially combining in situ CAR-T with other immunotherapies like checkpoint inhibitors.

This study marks a significant step forward in immunotherapy, demonstrating that in situ CAR-T cell generation is both feasible and effective in preclinical models.

Source.